Inflammatory disorders

A promising target to fight inflammatory bowel diseases

Inflammatory bowel diseases (IBDs), such as Crohn's disease or ulcerative colitis, arise when there is a dysregulation of the cell signaling pathways controlling the maintenance of homeostasis in the gut, leading to a chronic ...

Other

Roche to pay $7.1 bn for Telavant Holdings

Swiss pharmaceutical group Roche said Monday it will pay $7.1 billion to buy Telavant Holdings, a group developing new treatments for inflammatory bowel diseases.

page 4 from 40